Opportunities to Optimize Cancer Policies Panel Discussion

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Jul

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Breast Cancer Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease

Single-Fraction SBRT in Localized Prostate Cancer

Paving New ROADS in the Treatment of Brain Metastases With Implanted Tile-Based Radiation Therapy

FDA Approves Immunotherapy to Reduce Chronic GVHD in Patients Undergoing Stem Cell Transplant

Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma